ReviewAnnals of medicine2024
Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.
Review in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Article
- Clinical Features, Treatment, and Outcomes of Mucormycosis: A Retrospective Analysis of 13 Cases from a Single Center in Turkey (2015-2025).Tropical medicine and infectious disease · 2026Article
- Surgical therapy for pulmonary aspergillomas and mucormycosis: A 15-year experience from a single clinical center.JTCVS open · 2026Article
- Molecular Mechanisms of Mucormycosis Pathogenesis: Host-Pathogen Interactions and Immune Evasion.Pathogens (Basel, Switzerland) · 2026Review
- Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Auranofin and iodoquinol as promising repurposing drugs against filamentous fungi: antifungal activity and cellular alterations.Microbiology spectrum · 2026Article
- Review
- When cough leads to infarction: systemic arterial embolism as a sentinel complication of insidious pulmonary mucormycosis in an immunocompetent patient.BMC pulmonary medicine · 2026Article
- Rapid Diagnosis of Mucor and Aspergillus Co-Infection by Direct Microscopic Examination: A Case Report and Literature Review.Infection and drug resistance · 2026Article
- Angioinvasion severity and admission GCS predict outcomes in invasive central nervous system fungal infections.Frontiers in cellular and infection microbiology · 2026Article
- Fatal Cutaneous Mucormycosis Initially Misdiagnosed as Necrotizing Fasciitis in an Uncontrolled Diabetic Patient: A Case Report Highlighting Diagnostic Delay.International medical case reports journal · 2026Article
- Fungal Infections in Pediatric Patients With Hematologic Malignancies and Stem Cell Transplantation: Impact on the Upper and Lower Respiratory Systems.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Diagnostic Challenges in mNGS for Pulmonary Mucormycosis Presenting with Imaging Features Resembling Those of Lung Cancer.International medical case reports journal · 2026Article
- Clinical characteristics of tracheobronchial mucormycosis: a retrospective analysis of twenty cases.Annals of medicine · 2025Article
- Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis.BMC microbiology · 2025Article
- Management and Surgical Dressing Protocol for Cutaneous Mucormycosis After a Blast Injury: A Case Report.The American journal of case reports · 2025Article
- The Human Mycobiome: Composition, Immune Interactions, and Impact on Disease.International journal of molecular sciences · 2025Review
- Molecular epidemiology, diversity, and antifungal susceptibility profiles of clinical and environmental mucorales: a five-year multicenter study in Iran (2018-2023).BMC infectious diseases · 2025Article
- Clinical aspects and recent advances in fungal diseases impacting human health.The Journal of antimicrobial chemotherapy · 2025Review
- The Contribution of Human Antimicrobial Peptides to Fungi.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis review aims to summarize the epidemiology, etiology, pathogenesis, clinical manifestations, and current diagnostic and therapeutic approaches for mucormycosis. The goal is to improve understanding of mucormycosis and promote early diagnosis and treatment to reduce mortality.
methodsA comprehensive literature review was conducted, focusing on recent studies and data on mucormycosis. The review includes an analysis of the disease's epidemiology, etiology, and pathogenesis, as well as current diagnostic techniques and therapeutic strategies.
resultsMucormycosis is increasingly prevalent due to the growing immunocompromised population, the COVID-19 pandemic, and advances in detection methods. The pathogenesis is closely associated with the host immune status, serum-free iron levels, and the virulence of Mucorales. However, the absence of typical clinical manifestations complicates diagnosis, leading to missed or delayed diagnoses and higher mortality.
conclusionAn enhanced understanding of the epidemiology, pathogenesis, and clinical presentation of mucormycosis, along with the adoption of improved diagnostic and therapeutic approaches, is essential for reducing mortality rates associated with this opportunistic fungal infection. Early diagnosis and prompt treatment are critical to improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.